Tumor and serum beta-2-microglubulin expression in women with breast cancer

A. Del Giglio, E. L. Franco, H. Torloni, L. A. Marques, M. M. Brentani, Wadih Arap, M. Macchione, R. Chammas

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

To investigate whether the tumor expression of beta-2-microglobulin (β2-M) could serve as a marker of tumor biologic behavior, the authors studied specimens of breast carcinomas from 60 consecutive female patients. Presence of β2-M was analyzed by immunohistochemistry. No significant correlations were found between tumor β2-M expression and several histologic attributes such as type, histologic and nuclear grades, mitotic index, necrosis, vascular invasion, and lymphocytic infiltration. Likewise, β2-M was not associated with markers of disease extension such as TNM, (UICC, classification of malignant tumors) staging and axillary lymph node involvement or with estrogen, progesterone, and glucocorticoid receptor levels. However, there was a significantly positive association between tumor β2-M expression and the degree of lymphocytic infiltration in the tumor tissue. β2-M serum levels were determined by an enzyme-linked immunosorbent assay in samples from 22 of the above women. Although some of the highest values had been obtained in women with larger (T4) primary tumors, the authors failed to detect any statistical relationship between β2-M expression in the tumor with serum levels or between serum β2-M and the above histologic, laboratory, and clinical factors.

Original languageEnglish (US)
Pages (from-to)339-342
Number of pages4
JournalAmerican journal of clinical pathology
Volume92
Issue number3
StatePublished - Jan 1 1989
Externally publishedYes

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine

Cite this

Del Giglio, A., Franco, E. L., Torloni, H., Marques, L. A., Brentani, M. M., Arap, W., Macchione, M., & Chammas, R. (1989). Tumor and serum beta-2-microglubulin expression in women with breast cancer. American journal of clinical pathology, 92(3), 339-342.